Oregon Health & Science University
Portland, Oregon, 97239, United States
NCT Number: NCT01143012
The objective of this study is to determine whether group educational visits improve the quality of life of patients referred to the Dermatology Clinic. Secondary outcomes will be to determine whether group educational visits influences other key elements of patient care such as topical steroid usage, disease exacerbations, emergency visits, and phone calls to the office. Lastly, the investigators hope to evaluate which aspects of the educational visit were found to be the most helpful to families caring for children with atopic dermatitis (AD). Patients will be new atopic dermatitis referrals to OHSU dermatology and pediatric dermatology clinics. All consecutive patients with such appointments during a three month time period will be screened for participation in the study. Parents will be recruited via telephone. In the intervention group, parents will be invited to participate in a group education visit prior to their first appointment with a dermatologist. All parents in the study will fill out questionnaires. The children involved in the study will be assigned an eczema severity score during their routine visits, but this will be incorporated into the regular clinic assessment. The Childhood Atopic Dermatitis Impact Scale (CADIS) assesses the quality of life in households with children who have atopic dermatitis. The Eczema Area and Severity Index (EASI) measures the extent and severity of the patient's atopic dermatitis. The change in CADIS scores will be analyzed to determine if there is a more significant improvement in quality of life for the group in which parents receive the group eczema education visit.
Looking for future studies?
Notify Me2 month–6 year
All sexes
Interventional
Not applicable
Portland, Oregon, 97239, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
The control group will not attend the group eczema education session.
Time frame: 4 weeks
The primary outcome will be the difference between the two groups in CADIS score as measured at four weeks. CADIS is a validated outcome of pediatric quality of life in AD.
Time frame: Between 4 weeks and 4 months of the first visit.
EASI (Eczema Area and Severity Index) scores will be performed to assess extent of skin disease at an interval between 4 weeks and 4 months of the first visit.
Time frame: Between 4 weeks and 4 months of the first visit.
A chart review will be done to assess average monthly number of follow-up phone calls.
Time frame: Between 4 weeks and 4 months of the first visit.
A chart review will be done to assess average monthly number of urgent and emergency visits.
Oregon Health and Science University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05990725
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Augsburg, Germany
View Trial DetailsNCT07703215
Antioxidant Capacity, Atopic Dermatitis
Cheras, Kuala Lumpur, Malaysia
View Trial DetailsNCT07537751
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Kafr ash Shaykh, Kafr el-Sheikh Governorate, Egypt
View Trial DetailsNCT06474728
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Shanghai, Shanghai Municipality, China
View Trial Details